Novo Nordisk says Sanofi insulin lags degludec in study
COPENHAGEN, Oct 2 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, said its insulin degludec had shown 43 percent lower rates of night-time low blood sugar levels than glargine from rival drugmaker Sanofi .
Novo Nordisk said in a statement the data was presented on Tuesday at the Annual Meeting of the European Association for the Study of Diabetes (EASD).
The data had been collected in a two-year phase IIIa study, Novo Nordisk said.
(Reporting by Mette Fraende)
((Copenhagen newsroom, tel: +45 3396 9649, e-mail: firstname.lastname@example.org))